These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

330 related items for PubMed ID: 14594444

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Assessing preferences for prevention versus treatment using willingness to pay.
    Corso PS, Hammitt JK, Graham JD, Dicker RC, Goldie SJ.
    Med Decis Making; 2002; 22(5 Suppl):S92-101. PubMed ID: 12369235
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Use of FDA approved medications for Alzheimer's disease in mild dementia is associated with reduced informal costs of care.
    Behrens S, Rattinger GB, Schwartz S, Matyi J, Sanders C, DeBerard MS, Lyketsos CG, Tschanz JT.
    Int Psychogeriatr; 2018 Oct; 30(10):1499-1507. PubMed ID: 29559029
    [Abstract] [Full Text] [Related]

  • 8. The value of dementia care towards the end of life-A contingent valuation study.
    Bhattarai N, Mason H, Kernohan A, Poole M, Bamford C, Robinson L, Vale L.
    Int J Geriatr Psychiatry; 2020 May; 35(5):489-497. PubMed ID: 31912572
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US.
    Saint-Laurent Thibault C, Özer Stillman I, Chen S, Getsios D, Proskorovsky I, Hernandez L, Dixit S.
    J Med Econ; 2015 May; 18(11):930-43. PubMed ID: 26086535
    [Abstract] [Full Text] [Related]

  • 14. Valuing a hypothetical cure for rheumatoid arthritis using the contingent valuation methodology: the patient perspective.
    Fautrel B, Clarke AE, Guillemin F, Adam V, St-Pierre Y, Panaritis T, Fortin PR, Menard HA, Donaldson C, Penrod JR.
    J Rheumatol; 2005 Mar; 32(3):443-53. PubMed ID: 15742435
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Assessing the economic value of a new antidepressant. A willingness-to-pay approach.
    O'Brien BJ, Novosel S, Torrance G, Streiner D.
    Pharmacoeconomics; 1995 Jul; 8(1):34-45. PubMed ID: 10155600
    [Abstract] [Full Text] [Related]

  • 17. Measuring treatment preferences and willingness to pay for docetaxel in advanced ovarian cancer.
    Dranitsaris G, Elia-Pacitti J, Cottrell W.
    Pharmacoeconomics; 2004 Jul; 22(6):375-87. PubMed ID: 15099123
    [Abstract] [Full Text] [Related]

  • 18. Willingness to pay to assess patient preferences for therapy in a Canadian setting.
    Marra CA, Frighetto L, Goodfellow AF, Wai AO, Chase ML, Nicol RE, Leong CA, Tomlinson S, Ferreira BM, Jewesson PJ.
    BMC Health Serv Res; 2005 Jun 07; 5():43. PubMed ID: 15941474
    [Abstract] [Full Text] [Related]

  • 19.
    Lin JS, O'Connor E, Rossom RC, Perdue LA, Burda BU, Thompson M, Eckstrom E.
    ; 2013 11 07. PubMed ID: 24354019
    [Abstract] [Full Text] [Related]

  • 20. Cholinesterase inhibitors in dementia: yes, no, or maybe?
    Lemstra AW, Richard E, van Gool WA.
    Age Ageing; 2007 Nov 07; 36(6):625-7. PubMed ID: 17881419
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.